Dr. Steve Steinhubl, a leader in reinventing medicine through the convergence of healthcare and technology and an expert in physiology, has joined physIQ as Chief Medical Officer. Dr. Steinhubl will help advance the adoption of physIQ’s artificial intelligence (AI)-based analytics for improved clinical outcomes and lower costs.
“Over the last 5 years I’ve been fortunate enough to collaborate with the physIQ team on a number of projects,” says Steinhubl. “Their unwavering commitment to evidence-driven research is unparalleled. PhysIQ’s vision and drive for using cutting-edge digital technologies to enable more precise and individualized healthcare makes me extremely proud to be joining their amazing team. I look forward to helping expand upon fundamental research into early detection of medical conditions that would help drive better outcomes.”
Dr. Steinhubl has been the Director of Digital Medicine at Scripps Research Translational Institute (SRTI) for over 7.5 years. He will continue at SRTI as he takes on this new position. In his role at physIQ, Steinhubl will help drive the deployment of physIQ’s unique AI-based analytics platform to health systems and provider groups worldwide.
“Continuous Remote Patient Monitoring is emerging as a must-have capability for innovative-thinking, high-value healthcare systems. The technology from physIQ provides the right solution to enable and, in fact, lead the ongoing transformation in care delivery, as well as success in reimbursement models that are increasingly tied to value. Over the past 4 years, I’ve had the pleasure of working with Steve in his advisory role and am thrilled that he is joining the physIQ executive team,” said Dr. Stephen Ondra, physIQ’s former CMO. Ondra will continue as a Senior Advisor for physIQ.
Prior to joining Scripps, Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. He was Chief Cardiology Fellow at the Cleveland Clinic and served as Global Medical Vice President for The Medicines Company based in Zurich Switzerland. Steve has been principal investigator or helped lead over a dozen large-scale international randomized trials and has authored over 275 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.
“As we continue an incredible growth and innovation period for physIQ, Steve will help us lead adoption and expansion of our solutions for healthcare delivery and digitally enabled clinical trials. He is a recognized thought leader and researcher of digital medicine solutions, their adoption and the value they provide,” said Gary Conkright, CEO of physIQ. “Steve has been a long-time advisor and friend of physIQ, and we are honored to have him onboard as we strengthen our leadership position in the industry.”